{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-067136","form_type":"8-K","ticker":"CBLL","cik":"0001861107","company_name":"Ceribell, Inc.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.592418+00:00","generated_at":"2026-05-16T00:53:22.331487+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ceribell Q4 revenue $24.8M (+34% YoY); FY 2026 guidance $111-115M","bullets":["Full-year 2025 revenue $89.1M (+36% YoY); net loss $53.4M ($1.46/share).","Q4 gross margin 87%; active accounts 647; cash $159.3M.","FY 2026 revenue guidance $111-115M, representing 25-29% growth.","FDA 510(k) clearance for continuous delirium monitoring and neonatal seizure detection.","FDA Breakthrough Device Designation for large vessel occlusion stroke detection solution."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-067136","json":"https://secwatch.observer/filing/0001193125-26-067136.json","markdown":"https://secwatch.observer/filing/0001193125-26-067136.md","text":"https://secwatch.observer/filing/0001193125-26-067136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861107/000119312526067136/0001193125-26-067136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861107/000119312526067136/cbll-20260224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:53:22.331487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}